ASCO	American Society of Clinical Oncology
ASCT	Autologous stem cell transplantation
BIPN	Bortezomib-induced peripheral neuropathy
CAR-T	Chimeric Antigen Receptor T cell
CB1	Cannabinoid type 1 receptors
CB2	Cannabinoid type 2 receptors
CBD	Cannabidiol
CIPN	Chemotherapy-induced peripheral neuropathy
CRP	C-reactive Protein
CSCs	Cancer stem cells
DNMT	DNA methyltransferase
EGCG	Epigallocatechin 3 gallate
EZH2	Enhancer of zeste homolog2
IH	Integrative Hematology
IGF1	Insulin-like growth factor 1
IkB	NkB inhibitor
IL6	Interleukin 6
IL17	Interleukin 17
IMiDs	Immunomodulatory imide drugs
IO	Integrative Oncology
MAMs	Macrophages associated with myeloma
MBI	Mindfulness-based interventions
MDASI	MD Anderson Symptom Inventory
MGUS	Monoclonal gammopathy of unknown significance
MM	Multiple Myeloma
MMP2	Matrix metalloproteinase-2
MMP9	Matrix metalloproteinase-9
mTOR	Mammalian target of rapamycin
NCV	Nerve conduction velocity
NfkB	Nuclear factor kappa B
PI	Proteasome inhibitor
PIs	Proteasome inhibitors
QoL	Quality of life
RANKL	Receptor activator of nuclear factor kappa-Β ligand
RCT	Randomized-controlled trial
ROS	Reactive oxygen species
SIO	Society for Integrative Oncology
STAT3	Signal transducer and activator of transcription 3
THC	Delta-trans-9-tetrahydrocannabinol
TNFα	Tumor necrosis factor-α
TP53	Tumor protein p53
VEGF	Vascular endothelium growth factor
VDR	Vitamin D receptor